Dear patients and their family members and friends:

Our company's original new drug Chidamide (Epidaza?) has been accepted into category B of the catalogue of national basic medical insurance, industrial injury insurance and maternity insurance drugs ( 2017 edition ). It is limited to patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have received at least one systemic chemotherapy in the past.

Our company will adjust the retail price of Chidamide (Epidaza?) in medical institutions in the region (including retail pharmacies of Chidamide designated for reimbursement by medical insurance) according to the medical insurance catalog implementation plan of the 2017 version published by various provinces (cities, districts) in terms of the medical insurance payment standard. The adjusted retail price will be 9240 yuan / box.

Please refer to the announcements of human resources, social security network and drug centralized purchasing network of all provinces (cities, districts) for the specific implementation time of price adjustment. During the transitional period of medical insurance, our company specially formulated the corresponding transitional period policy according to the relevant requirements and the social responsibility of the enterprise. Search (http:// www.aipusha.com) for details. I apologize for any inconvenience, and thank you for your understanding and support.